The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
The p53 pathway in breast cancer
Open accessAbstract
p53 mutation remains the most common genetic change identified in human neoplasia. In breast cancer, p53 mutation is associated with more aggressive disease and worse overall survival. The frequency of mutation in p53 is, however, lower in breast cancer than in other solid tumours. Changes, both genetic and epigenetic, have been identified in regulators of p53 activity and in some downstream transcriptional targets of p53 in breast cancers that express wild-type p53. Molecular pathological analysis of the structure and expression of constituents of the p53 pathway is likely to have value in diagnosis, in prognostic assessment and, ultimately, in treatment of breast cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
p53 mutation in plasma DNA and its prognostic value in breast cancer patients.
Shao, Z. M., Wu, J., Shen, Z., & Nguyen, M. (2001) · PubMed · Cited by 64
RetractedVogelstein, B., Lane, D., & Levine, A. J. (2000) · Nature · doi:10.1038/35042675 · Cited by 6,607
Germ Line p53 Mutations in a Familial Syndrome of Breast Cancer, Sarcomas, and Other Neoplasms
Malkin, D., Li, F. P., Strong, L. C., Fraumeni, J. F., Nelson, C. E., Kim, D. H., Kassel, J., Gryka, M. A., Bischoff, F. Z., Tainsky, M. A., et al. (1990) · Science · doi:10.1126/science.1978757 · Cited by 3,765
Promoter Hypermethylation and BRCA1 Inactivation in Sporadic Breast and Ovarian Tumors
Esteller, M. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.7.564 · Cited by 1,233 · cited 1×
“Indeed, methylation-dependent silencing of BRCA1 expression occurs commonly in medullary breast cancers [14].”
BackgroundHeterozygous Germ Line hCHK2 Mutations in Li-Fraumeni Syndrome
Bell, D. W., Varley, J. M., Szydlo, T. E., Kang, D. H., Wahrer, D. C. R., Shannon, K. E., Lubratovich, M., Verselis, S. J., Isselbacher, K. J., Fraumeni, J. F., et al. (1999) · Science · doi:10.1126/science.286.5449.2528 · Cited by 904
Regulation ofp53downstream genes
El-Deiry, W. S. (1998) · Seminars in Cancer Biology · doi:10.1006/scbi.1998.0097 · Cited by 800
Aas, T., Børresen, A.-L., Geisler, S., Smith-Sørensen, B., Johnsen, H., Varhaug, J. E., Akslen, L. A., & Lønning, P. E. (1996) · Nature Medicine · doi:10.1038/nm0796-811 · Cited by 736
Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome.
Sigal, A., & Rotter, V. (2000) · PubMed · Cited by 666
ASPP Proteins Specifically Stimulate the Apoptotic Function of p53
Samuels-Lev, Y., O'Connor, D. J., Bergamaschi, D., Trigiante, G., Hsieh, J.-K., Zhong, S., Campargue, I., Naumovski, L., Crook, T., & Lu, X. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00367-7 · Cited by 664
Self-citationGenetic and immunochemical analysis of mutant p53 in human breast cancer cell lines.
Bártek, J., Iggo, R. D., Gannon, J., & Lane, D. P. (1990) · PubMed · Cited by 603
Mutations truncating the EP300 acetylase in human cancers
Gayther, S. A., Batley, S. J., Linger, L., Bannister, A., Thorpe, K., Chin, S.-F., Daigo, Y., Russell, P., Wilson, A., Sowter, H. M., et al. (2000) · Nature Genetics · doi:10.1038/73536 · Cited by 587
Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion.
Moll, U. M., Riou, G., & Levine, A. J. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.15.7262 · Cited by 575
BRCA1 physically associates with p53 and stimulates its transcriptional activity
Zhang, H., Somasundaram, K., Peng, Y., Tian, H., Zhang, H., Bi, D., Weber, B. L., & El-Deiry, W. S. (1998) · Oncogene · doi:10.1038/sj.onc.1201932 · Cited by 492
Compromised HOXA5 function can limit p53 expression in human breast tumours
Raman, V., Martensen, S. A., Reisman, D., Evron, E., Odenwald, W. F., Jaffee, E., Marks, J., & Sukumar, S. (2000) · Nature · doi:10.1038/35016125 · Cited by 482
High frequency of hypermethylation at the 14-3-3 σ locus leads to gene silencing in breast cancer
Ferguson, A. T., Evron, E., Umbricht, C. B., Pandita, T. K., Chan, T. A., Hermeking, H., Marks, J. R., Lambers, A. R., Futreal, P. A., Stampfer, M. R., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.100566997 · Cited by 444
Stankovic, T., Kidd, A. M. J., Sutcliffe, A., McGuire, G. M., Robinson, P., Weber, P., Bedenham, T., Bradwell, A. R., Easton, D. F., Lennox, G. G., et al. (1998) · The American Journal of Human Genetics · doi:10.1086/301706 · Cited by 400
In vivo gene expression profile analysis of human breast cancer progression.
Sgroi, D. C., Teng, S., ROBINSON, G. C., LeVangie, R., Hudson, J. R., & Elkahloun, A. G. (1999) · PubMed · Cited by 390
p63, a p53 Homologue, Is a Selective Nuclear Marker of Myoepithelial Cells of the Human Breast
Barbareschi, M., Pecciarini, L., Cangi, M. G., Macrì, E., Rizzo, A., Viale, G., & Doglioni, C. (2001) · The American Journal of Surgical Pathology · doi:10.1097/00000478-200108000-00010 · Cited by 384
Catteau, A., Harris, W. H., Xu, C.-F., & Solomon, E. (1999) · Oncogene · doi:10.1038/sj.onc.1202509 · Cited by 354
Geisler, S. B., Lønning, P. E., Aas, T., Johnsen, H., Fluge, Ø., Haugen, D. F., Lillehaug, J. R., Akslen, L. A., & Børresen‐Dale, A. (2001) · PubMed · Cited by 326
Somatic mutations in the p53 gene and prognosis in breast cancer: a meta-analysis
Pharoah, P. D. P., Day, N. E., & Caldas, C. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690628 · Cited by 308
Hypermethylation of 14-3-3 σ (stratifin) is an early event in breast cancer
Umbricht, C. B., Evron, E., Gabrielson, E., Ferguson, A. T., Marks, J., & Sukumar, S. (2001) · Oncogene · doi:10.1038/sj.onc.1204438 · Cited by 291
Genetic basis for p53 overexpression in human breast cancer.
Davidoff, A. M., Humphrey, P. A., Iglehart, J. D., & Marks, J. R. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.11.5006 · Cited by 285
Kandioler-Eckersberger, D., Ludwig, C., Rudas, M., Kappel, S., Janschek, E., Wenzel, C., Schlagbauer‐Wadl, H., Mittlböck, M., Gnant, M., Steger, G., et al. (2000) · PubMed · Cited by 280
p53 regulates the expression of the tumor suppressor gene maspin
Zou, Z., Gao, C., Nagaich, A. K., Connell, T., Saito, S., Moul, J. W., Seth, P., Appella, E., & Srivastava, S. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.9.6051 · Cited by 221
Greenblatt, M. S., Chappuis, P. O., Bond, J. P., Hamel, N., & Foulkes, W. D. (2001) · PubMed · Cited by 196
Vahteristo, P., Tamminen, A., Karvinen, P., Eerola, H., Eklund, C., Aaltonen, L. A., BLOMQVIST, C. P., Aittomäki, K., & Nevanlinna, H. A. (2001) · PubMed · Cited by 180
p53 mutations occur in aggressive breast cancer.
Mazars, R., Spinardi, L., BenCheikh, M., Simony-Lafontaine, J., Jeanteur, P., & Theillet, C. G. (1992) · PubMed · Cited by 156
Spectrum of ATM gene mutations in a hospital-based series of unselected breast cancer patients.
Dörk, T., Bendix, R., Bremer, M., Rades, D., Klöpper, K., Nicke, M., Skawran, B., Hector, A., Yamini, P., Steinmann, D., et al. (2001) · PubMed · Cited by 151
Linderholm, B. K., Lindahl, T., Holmberg, L., Klaar, S., Lennerstrand, J., Henriksson, R., & Bergh, J. C. S. (2001) · PubMed · Cited by 149
Molecular epidemiology and carcinogenesis: endogenous and exogenous carcinogens
Hussain, S. P., & Harris, C. C. (2000) · Mutation Research/Reviews in Mutation Research · doi:10.1016/s1383-5742(00)00015-6 · Cited by 124
Maass, N., Teffner, M., Rösel, F., Pawaresch, R., Jonat, W., Nagasaki, K., & Rudolph, P. (2001) · The Journal of Pathology · doi:10.1002/path.948 · Cited by 118
Frequency of p53 mutations in breast carcinomas from Ashkenazi Jewish carriers of BRCA1 mutations.
Phillips, K., Nichol, K., Ozçelik, H., Knight, J., Done, S., Goodwin, P., & Andrulis, I. (1999) · Journal of the National Cancer Institute · doi:10.1093/jnci/91.5.469 · Cited by 111
Smith, P. D., Crossland, S., Parker, G. A., Osin, P., Brooks, L. A., Waller, J., Philp, E., Crompton, M. R., Gusterson, B. A., Allday, M. J., et al. (1999) · Oncogene · doi:10.1038/sj.onc.1202565 · Cited by 103
Self-citationConcomitant inactivation of p53 and Chk2 in breast cancer
Sullivan, A., Yuille, M., Repellin, C., Reddy, A., Reelfs, O., Bell, A., Dunne, B., Gusterson, B. A., Osin, P., Farrell, P. J., et al. (2002) · Oncogene · doi:10.1038/sj.onc.1205207 · Cited by 91
Self-citationMutation analysis of the CHK2gene in families with hereditary breast cancer
Allinen, M., Huusko, P., Mäntyniemi, S., Launonen, V, & Winqvist, R. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.1858 · Cited by 85
p53 Mutation as a Genetic Trait of Typical Medullary Breast Carcinoma
de Crémoux, P., Vincent‐Salomon, A., Liva, S., Dendale, R., Bouchindhomme, B., Martin, E., Sastre‐Garau, X., Magdelénat, H., Fourquet, A., & Soussi, T. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.7.641 · Cited by 82
WAF1/Cip1 gene polymorphism and expression in carcinomas of the breast, ovary, and endometrium.
Lukas, J. L., Groshen, S. G., Saffari, B., Niu, N., Reles, A., Wen, W., Felix, J. C., Jones, L. A., Hall, F. L., & Press, M. F. (1997) · Europe PMC (PubMed Central) · Cited by 80
Heterogeneity in the clinical phenotype of TP53 mutations in breast cancer patients
Alsner, J., Yilmaz, M. K., Guldberg, P., Hansen, L. L., & Overgaard, J. (2000) · Breast Cancer Research · doi:10.1186/bcr109 · Cited by 79
Vogelstein, B., & Kinzler, K. W. (2001) · Nature · doi:10.1038/35091170 · Cited by 77
p53 Missense Mutations in Microdissected High-Grade Ductal Carcinoma In Situ of the Breast
Done, S. J., Eskandarian, S., Bull, S. B., Redston, M. S., & Andrulis, I. L. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.9.700 · Cited by 71
MDM2 gene amplification in human breast cancer
Quesnel, B., Preudhomme, C., Fournier, J., Fenaux, P., & Peyrat, J. (1994) · European Journal of Cancer · doi:10.1016/0959-8049(94)90128-7 · Cited by 67
Gentile, M., Waltersson, M. A., Schön, F., & Wingren, S. (2001) · Oncogene · doi:10.1038/sj.onc.1204993 · Cited by 61
Wild Type p73 Overexpression and High-Grade Malignancy in Breast Cancer
Domínguez, G., Silva, J. M., Silva, J., Garcia, J. M., Sánchez, A., Navarro, A., Gallego, I., Provencio, M., España, P., & Bonilla, F. (2001) · Breast Cancer Research and Treatment · doi:10.1023/a:1010624717311 · Cited by 57
Abnormal expression of the ATM and TP53 genes in sporadic breast carcinomas.
Angèle, S., Treilleux, I., Tanière, P., Martel‐Planche, G., Vuillaume, M., Bailly, C., Bremond, A. G., Montesano, R., & Hall, J. A. (2000) · PubMed · Cited by 56
Increased p53 mutation frequency during tumor progression--results from a breast cancer cohort.
Norberg, T., Klaar, S., Kärf, G., et al. (2001) · PubMed · Cited by 52
Analysis of genetic and epigenetic processes that influence p14ARF expression in breast cancer
Silva, J., Domínguez, G., Silva, J. M., García, J. M., Gallego, I., Corbacho, C., Provencio, M., España, P., & Bonilla, F. (2001) · Oncogene · doi:10.1038/sj.onc.1204617 · Cited by 52
WAF1/CIP1 protein expression in human breast tumors
Diab, S., Yu, Y.-Y., Hilsenbeck, S. G., Allred, D. C., & Elledge, R. M. (1997) · Breast Cancer Research and Treatment · doi:10.1023/a:1005752829260 · Cited by 36
Genetic Alterations of the p14ARF-hdm2-p53 Regulatory Pathway in Breast Carcinoma
Ho, G. H., Calvano, J. E., Bisogna, M., Abouezzi, Z. E., Borgen, P. I., Cordon‐Cardo, C., & Zee, K. J. V. (2001) · Breast Cancer Research and Treatment · doi:10.1023/a:1010686518990 · Cited by 26
Cited by
Apoptosis in cancer: from pathogenesis to treatment
Wong, R. S. (2011) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-30-87 · Cited by 2,836
A Comprehensive Immunologic Portrait of Triple-Negative Breast Cancer
Liu, Z., Li, M., Jiang, Z., & Wang, X. (2018) · Translational Oncology · doi:10.1016/j.tranon.2018.01.011 · Cited by 275
Pairawan, S., Zhao, M., Yuca, E., Annis, A., Evans, K., Sutton, D., Carvajal, L., Ren, J.-G., Santiago, S., Guerlavais, V., et al. (2021) · Breast Cancer Research · doi:10.1186/s13058-021-01406-x · Cited by 73
Rajendran, B. K., & Deng, C.-X. (2017) · Oncotarget · doi:10.18632/oncotarget.17225 · Cited by 73
The Hypoxia-inducible Factor Renders Cancer Cells More Sensitive to Vitamin C-induced Toxicity
Tian, W., Wang, Y., Xu, Y., Guo, X., Wang, B., Sun, L., Liu, L., Cui, F., Zhuang, Q., Bao, X., et al. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.538157 · Cited by 59
Metadata
- Authors
- Gasco, M., Shami, S., & Crook, T.
- Venue
- Breast Cancer Research
- Published
- 2002-04
- Volume
- 4
- Issue
- 2
- Pages
- 70-6
- ISSN
- 1465-5411 (ISSN-L)
- 1465-542X
- OpenAlex
- W1663251599
- Cited by
- 393
- References
- 49
- FWCI
- 2.19
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.